Novocure Stock
Novocure Ltd
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- Switzerland
- CEO
- Frank Leonard
- Employees
- 1,605
- Market cap
- $1.6 B
- IPO
- 02/10/2015
Novocure Ltd is a healthcare company engaged in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers. The company was incorporated in 2000 and is headquartered in Baar, Switzerland. Its TTFields device portfolio includes Optune Gio,…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Novocure stock: price history
1D
-2.4%
1W
-3.5%
1M
-13.3%
6M
+9.7%
YTD
+8.8%
1Y
+0.3%
2Y
-21.3%
5Y
-87.5%
10Y
+92.0%
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~34% stronger price swings than usual
Ask the agents about Novocure
Analyst assessment of Novocure
PRICE TARGET LOW
US$20.00
CONSENSUS
US$26.00
MEDIAN
US$26.00
PRICE TARGET HIGH
US$32.00
0
STRONG BUY
9
BUY
5
HOLD
1
SELL
0
STRONG SELL
15
TOTAL · Buy
As of: 24/07/2026
Novocure stock metrics
P/E
-10.82
P/B
4.83
EV/EBITDA
-13.4
RETURN ON EQUITY
-4.6%
NET MARGIN
-8.5%
DEBT/EQUITY
0.69
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.8%
FLOAT SHARES
96,424,142
AVG. DAILY VOLUME (30D)
1,328,416
Insider transactions (SEC)
Danziger Asaf
Leonard Frank X
Ben Arye Barak
Puri Michal Nath
HILLEMAN JERYL L
Institutional holders
Comparable stocks
Frequently asked questions about Novocure stock
What does Novocure do?
Novocure Ltd is a company in the Healthcare sector, Medical - Devices industry, headquartered in Switzerland.
The CEO is Frank Leonard, the company employs around 1,605 people.
The IPO was on 02/10/2015; the stock trades on NASDAQ under the ticker NVCR.
What do analysts say about Novocure stock?
15 analysts rate the stock, the consensus is Buy (as of 24/07/2026).
The average price target is US$26.00, ranging from US$20.00 to US$32.00, with a median of US$26.00.
This is an external assessment, not a statement by Market Jury.
When does Novocure report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly 34% stronger than usual.
Does Novocure pay a dividend?
No, Novocure currently does not pay a dividend.
Which stocks are comparable to Novocure?
Comparable stocks include Sonova Holding, Kuros Biosciences, Abbott Laboratories, Medtronic, Stryker, Boston Scientific, Edwards Lifesciences and Siemens Healthineers.
How can I get Novocure stock analyzed?
Clicking "Analyze stock" lets five strategies assess Novocure against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.